Table 2: Implementation of preventive measures for VAE other than VAP.
LTVV: Low tidal volume ventilation;
Short-acting: usage of Propofol and Dexmedetomidine>50%.
Long-acting: usage of Benzodiazepines >50%.
S: Sucralfate; PPI: proton pump inhibitors; H2: H2 receptor blockers.
Dominant usage of S: the usage of Sucralfate ≥1/3.
Dominant usage of PPI and/or H2: the usage of Sucralfate < 1/3.
| Monitoring items | N (%) |
| Sedative |
| Short-acting | 22 (68.7) |
| Dexmedetomidine | 17 (53.1) |
| Propofol | 5 (15.6) |
| Long-acting |
| Benzodiazepines | 10 (31.3) |
| Fluid balance control |
| Negative | 8 (25.0) |
| Non-negative | 22 (68.8) |
| LTVV |
| 0~7mL/kg | 3 (9.4) |
| 7-10mL/kg | 25 (78.1) |
| Anti-ulcer drugs |
| Dominant usage of S | 6 (18.7) |
| Dominant usage of PPI and/or H2 | 19 (59.4) |